이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PureTech Health 관리

관리 기준 확인 2/4

PureTech Health's CEO는 Bharatt Chowrira, Apr2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 2.49M, 23.1% 로 구성됩니다. 23.1% 급여 및 76.9% 보너스(회사 주식 및 옵션 포함). 는 € 254.46K 가치에 해당하는 회사 주식의 0.037% 직접 소유합니다. 254.46K. 경영진과 이사회의 평균 재임 기간은 각각 2.2 년과 7.7 년입니다.

주요 정보

Bharatt Chowrira

최고 경영자

US$2.5m

총 보상

CEO 급여 비율	23.1%
CEO 임기	less than a year
CEO 소유권	0.04%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	7.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bharatt Chowrira 의 보수는 PureTech Health 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	US$2m	US$575k	-US$66m
Sep 30 2023	n/a	n/a	-US$56m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$49m
Dec 31 2022	US$988k	US$530k	-US$50m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$1m	US$500k	-US$61m

보상 대 시장: Bharatt 의 총 보상 ($USD 2.49M )은 German 시장( $USD 1.31M ).

보상과 수익: 회사가 수익성이 없는 동안 Bharatt 의 보상이 증가했습니다.

CEO

Bharatt Chowrira (59 yo)

less than a year

테뉴어

US$2,490,425

보상

Dr. Bharatt M. Chowrira, J. D. Ph. D. served as Chief Business and Operating Officer at PureTech Health plc. since January 2022 until 2024 and serves as its Chief Executive Officer from April 09, 2024 and...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bharatt Chowrira	CEO & Executive Director	less than a year	US$2.49m	0.042% $ 221.8k
Daphne Zohar	Founder	no data	US$4.74m	5.34% $ 28.3m
Robert Langer	Co-Founder & Non-Executive Director	no data	US$135.00k	1.24% $ 6.6m
Eric Elenko	Co-Founder & President	less than a year	데이터 없음	데이터 없음
David Elmaleh	Co-Founder & Senior Advisor	no data	데이터 없음	데이터 없음
Eric Green	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Allison Talbot	Head of Communications & Investor Relations	no data	데이터 없음	데이터 없음
Charles Sherwood	General Counsel & Company Secretary	less than a year	데이터 없음	데이터 없음
Spencer Ball	Senior Vice President of Human Resources	3.9yrs	데이터 없음	데이터 없음
Aleksandra Filipovic	Head of Oncology	3.9yrs	데이터 없음	데이터 없음
Cheryl Murphy	Head of Grants Management & Strategy	3.9yrs	데이터 없음	데이터 없음
Anita Terpstra	Senior VP & Head of Intellectual Property	3.9yrs	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 0VQ 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bharatt Chowrira	CEO & Executive Director	3.3yrs	US$2.49m	0.042% $ 221.8k
Daphne Zohar	Founder	less than a year	US$4.74m	5.34% $ 28.3m
Robert Langer	Co-Founder & Non-Executive Director	no data	US$135.00k	1.24% $ 6.6m
David Elmaleh	Co-Founder & Senior Advisor	no data	데이터 없음	데이터 없음
Raju Kucherlapati	Chair & Senior Independent Director	10.4yrs	US$172.50k	1.04% $ 5.5m
John LaMattina	Independent Non-Executive Director	15.4yrs	US$137.75k	0.65% $ 3.4m
Bennett Shapiro	Board Advisor	4yrs	US$68.94k	데이터 없음
R. Anderson	Advisor	7.7yrs	데이터 없음	데이터 없음
James Collins	Advisor	8.6yrs	데이터 없음	데이터 없음
Donald Ingber	Senior Advisor	8.4yrs	데이터 없음	데이터 없음
Frederick Frank	Senior Advisor	no data	데이터 없음	데이터 없음
Sharon Barber-Lui	Independent Non-Executive Director	2.3yrs	US$135.00k	0.0090% $ 47.7k

7.7yrs

평균 재임 기간

74yo

평균 연령

경험이 풍부한 이사회: 0VQ 의 이사회는 경험(평균 재직 기간 7.7 년)으로 간주됩니다.

PureTech Health 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

PureTech Health plc Announces Chief Executive Officer Changes

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

PureTech Health plc Announces Executive Changes

Recent updates

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in FY 2022)

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New minor risk - Financial data availability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

New minor risk - Share price stability

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

First half 2023 earnings released: US$0.09 loss per share (vs US$0.098 loss in 1H 2022)

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in FY 2021)

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

First half 2022 earnings released: US$0.098 loss per share (vs US$0.26 loss in 1H 2021)

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.021 profit in FY 2020)

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought €85k worth of stock

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS

First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020)

President recently bought €97k worth of stock

PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202

President recently bought €81k worth of stock

PureTech Health plc (LSE:PRTC) acquired the remaining 22% stake in Alivio Therapeutics.

Puretech’s Gelesis Presents Plenity Data at American Association of Clinical Endocrinology 2021

COO, Secretary & Executive Director has left the company

Full year 2020 earnings released

PureTech Health plc Announces Executive Changes

PureTech Health plc to Report Fiscal Year 2020 Final Results on Apr 15, 2021

PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release

New 90-day high: €4.70

PureTech Names Bharatt Chowrira to Board of Directors

PureTech Health plc Appoints Bharatt Chowrira to its Board of Directors

PureTech Health plc Announces Management Appointments

New 90-day high: €4.66

PureTech Announces the Appointment of George Farmer as Chief Financial Officer

Investor sentiment improved over the past week